King's College London

Psychedelics continue to garner attention as possible treatments for diverse mental health conditions. Now, Compass Pathways (NASDAQ: CMPS) will undertake a study to evaluate psilocybin’s effects on autistic adults. The study, named Psilaut, is being co-sponsored by the...